Use of IL-23 antagonists for treatment of infection
View Patent ↗Methods and compositions comprising antagonists of IL-23 are provided for the treatment of infections, such as chronic bacterial, viral and fungal infections.
1. A method of enhancing a Th1 immune response in a subject having a chronic fungal infection selected from the group consisting of candidiasis and aspergillosis, comprising administering an antagonist of IL-23.
2. The method of claim 1 wherein the enhanced Th1 immune response comprises a 2-fold or greater increase in the percentage of CD4 + T cells expressing IFN-γ compared with the percentage of CD4 + T cells expressing IFN-γ prior to administering said antagonist of IL-23.
3. The method of claim 1 wherein the enhanced Th1 immune response comprises a 2-fold or greater decrease in the percentage of CD4 + T cells expressing IL-17 compared with the percentage of CD4 + T cells expressing IL-17 prior to administering said antagonist of IL-23.
4. The method of claim 1 , wherein the antagonist of IL-23 is a binding compound that binds to IL-23p19.
5. The method of claim 1 , wherein the antagonist of IL-23 is a binding compound that binds to IL-23R.
6. The method of claim 4 wherein the binding compound is an antibody or antigen binding fragment thereof.
7. The method of claim 5 wherein the binding compound is an antibody or antigen binding fragment thereof.
8. The method of claim 4 wherein the binding compound is an antibody fragment selected from the group consisting of Fab, Fab′, Fab′-SH, Fv, scFv, F(ab′) 2 , a single chain antibody, and a diabody.
9. The method of claim 5 wherein the binding compound is an antibody fragment selected from the group consisting of Fab, Fab′, Fab′-SH, Fv, scFv, F(ab′) 2 , a single chain antibody, and a diabody.
10. The method of claim 6 wherein the antibody is a humanized or fully human antibody or antigen binding fragment thereof.
11. The method of claim 7 wherein the antibody is a humanized or fully human antibody or antigen binding fragment thereof.
12. The method of any of the preceding claim 1 further comprising administering at least one of an antagonist of IL-17A, IL-6 or TGF-β.